NAMPT and hepatocellular carcinoma: Although the prevalence of the TT genotype was lower in the HBV-LC (11.4%) and HBV-HCC (10.7%) patients when compared with the control group (15.2%), the distribution of the visfatin genotype and allele frequencies did not differ significantly between the patient and the control groups (P > 0.05).